A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta

Cellular Immunology

Volumn 290, Issue 1, 2014, Pages 52-61

  Lee, Hae mi ^a   Kim, Kyung Sup ^a   Kim, Jongsun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Immunosuppression; Interleukin 10 (IL 10); Interleukin 4 (IL 4); Natural killer (NK) cell; Signaling; Transcription regulation; Transforming growth factor beta (TGF )

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYC PROTEIN; PROTEIN C JUN; PROTEIN C MYB; PROTEIN KINASE SYK; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ASSAY; CELL ACTIVATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

IMMUNOSUPPRESSION; INTERLEUKIN-10 (IL-10); INTERLEUKIN-4 (IL-4); NATURAL KILLER (NK) CELL; SIGNALING; TRANSCRIPTION REGULATION; TRANSFORMING GROWTH FACTOR BETA (TGF-Β);

ANTHRACENES; CELL LINE; CELL PROLIFERATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MAP KINASE KINASE 1; NEOPLASMS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MYB; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 84901439290     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.05.001     Document Type: Article

References (41)

1. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
2. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
3. Langers I., Renoux V.M., Thiry M., Delvenne P., Jacobs N. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012, 6:73-82.
4. Schleypen J.S., Baur N., Kammerer R., Nelson P.J., Rohrmann K., Grone E.F., et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 2006, 12:718-725.
5. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
6. Konjevic G., Jurisic V., Jovic V., Vuletic A., Mirjacic Martinovic K., Radenkovic S., et al. Investigation of NK cell function and their modulation in different malignancies. Immunol. Res. 2012, 52:139-156.
7. Konjevic G., Jurisic V., Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res. Treat. 2001, 66:255-263.
8. Mirjacic Martinovic K., Konjevic G., Babovic N., Inic M. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. J. Surg. Res. 2011, 171:637-649.
9. Stojanovic A., Cerwenka A. Natural killer cells and solid tumors. J. Innate Immun. 2011, 3:355-364.
10. Stojanovic A., Correia M.P., Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron. 2013, 6:135-146.
11. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 2007, 7:329-339.
12. Shariat S.F., Shalev M., Menesses-Diaz A., Kim I.Y., Kattan M.W., Wheeler T.M., et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 2001, 19:2856-2864.
13. Li X., Yue Z.C., Zhang Y.Y., Bai J., Meng X.N., Geng J.S., et al. Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J. Clin. Lab. Anal. 2008, 22:164-171.
14. + T cells in glioma patients. Neuro-oncology 2010, 12:7-13.
15. Wilson E.B., El-Jawhari J.J., Neilson A.L., Hall G.D., Melcher A.A., Meade J.L., et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 2011, 6:e22842.
16. Castriconi R., Cantoni C., Della Chiesa M., Vitale M., Marcenaro E., Conte R. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4120-4125.
17. Bellone G., Aste-Amezaga M., Trinchieri G., Rodeck U. Regulation of NK cell functions by TGF-beta 1. J. Immunol. (Baltimore, Md: 1950) 1995, 155:1066-1073.
18. Ghio M., Contini P., Negrini S., Boero S., Musso A., Poggi A. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur. J. Immunol. 2009, 39:3459-3468.
19. Yigit R., Massuger L.F., Zusterzeel P.L., Pots J., Figdor C.G., Torensma R. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. Int. J. Gynecol. Cancer 2011, 21:1241-1247.
20. Szkaradkiewicz A., Karpinski T.M., Drews M., Borejsza-Wysocki M., Majewski P., Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J. Biomed. Biotechnol. 2010, 90:901564.
21. Jarnicki A.G., Lysaght J., Todryk S., Mills K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. (Baltimore, Md: 1950) 2006, 177:896-904.
22. Takeshi Ueda Marianne D., Sadar H.S., Koichiro Akakura, Shinichi Sakamoto M.S., Takahito Suyama, Takashi Imamoto, Akira Komiya NYaTI Interleukin-4 in patients with prostate cancer. Anticancer Res. 2005, 7:4595-4598.
23. Nagai S., Toi M. Interleukin-4 and breast cancer. Breast Cancer 2000, 7:181-186.
24. Orditura M., Romano C., De Vita F., Galizia G., Lieto E., Infusino S., et al. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol. Immunother. 2000, 49:530-536.
25. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004, 294:15-22.
26. Lozzio B.B., Lozzio C.B. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk. Res. 1979, 3:363-370.
27. Jost S., Quillay H., Reardon J., Peterson E., Simmons R.P., Parry B.A., et al. Changes in cytokine levels and NK cell activation associated with influenza. PLoS One 2011, 6:e25060.
28. Minami Y., Nakagawa Y., Kawahara A., Miyazaki T., Sada K., Yamamura H., et al. Protein tyrosine kinase Syk is associated with and activated by the IL-2 receptor: possible link with the c-myc induction pathway. Immunity 1995, 2:89-100.
29. Gannett P.M., Ye J., Ding M., Powell J., Zhang Y., Darian E., et al. Activation of AP-1 through the MAP kinase pathway: a potential mechanism of the carcinogenic effect of arenediazonium ions. Chem. Res. Toxicol. 2000, 7:1020-1027.
30. Deniz G., Akdis M., Aktas E., Blaser K., Akdis C.A. Human NK1 and NK2 subsets determined by purification of IFN-gamma-secreting and IFN-gamma-nonsecreting NK cells. Eur. J. Immunol. 2002, 32:879-884.
31. Noyko Stanilov, Tashko Deliysky, Jovcho Jovchev, Spaska Stanilova Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Science (New York, NY) 2011, 41:159-163.
32. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science (New York, NY) 1995, 268:251-255.
33. Zhou Y.J., Magnuson K.S., Cheng T.P., Gadina M., Frucht D.M., Galon J., et al. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol. Cell. Biol. 2000, 20:4371-4380.
34. Pelengaris S., Khan M., Evan G. C-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2002, 2:764-776.
35. Sullivan R.P., Leong J.W., Fehniger T.A. MicroRNA regulation of natural killer cells. Front. Immunol. 2013, 4:44.
36. Nausch N., Florin L., Hartenstein B., Angel P., Schorpp-Kistner M., Cerwenka A. Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J. Immunol. (Baltimore, Md: 1950) 2006, 176:7-11.
37. Bennett B.L., Sasaki D.T., Murray B.W., O'leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13681-13686.
38. Song H., Hur D.Y., Kim K.E., Park H., Kim T., Kim C.W., et al. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol. 2006, 242:39-45.
39. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 1995, 270:27489-27494.
40. Trotta R., Kanakaraj P., Perussia B. Fc gamma R-dependent mitogen-activated protein kinase activation in leukocytes: a common signal transduction event necessary for expression of TNF-alpha and early activation genes. J. Exp. Med. 1996, 184:1027-1035.
41. Mainiero F., Gismondi A., Soriani A., Cippitelli M., Palmieri G., Jacobelli J., et al. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J. Exp. Med. 1998, 188:1267-1275.